Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
A recent MAIC study comparing mepolizumab and dupilumab in eosinophilic COPD patients found no significant difference between the treatments in reducing exacerbations or improving quality of life.
This article reviews mepolizumab efficacy in COPD patients with variable blood eosinophil counts, showing benefits even with intermittent eosinophilia, expanding treatable phenotypes beyond persistent elevation.
This study reveals multiple distinct molecular mechanisms, including epithelial and macrophage pathways, that contribute to residual asthma exacerbations in children treated with mepolizumab, highlighting the complexity of airway inflammati
Mepolizumab significantly reduces moderate to severe COPD exacerbations in patients with elevated eosinophils on triple inhaled therapy, marking a promising advance for eosinophilic COPD management.